Orange Book product · Generic (ANDA)
RIVASTIGMINE
RIVASTIGMINE
At a glance
Sep 03, 2015
Approved
Generic (ANDA)
Application
Not listed
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Sep 03, 2015
10 yr 11 mo ago
Today
Pharmaceutical detail
Active ingredient
RIVASTIGMINE
Strength
4.6MG/24HR
Dosage form
FILM, EXTENDED RELEASE
Route
TRANSDERMAL
TE code
Not listed
Application
ANDA 204403
Product number
001
Marketing status
DISCN
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of RIVASTIGMINE
- 2007EXELONBrand (NDA)
NDA 022083 · SANDOZ
- 2025RIVASTIGMINEGeneric (ANDA)
ANDA 215445 · YICHANG HUMANWELL
- 2019RIVASTIGMINEGeneric (ANDA)
ANDA 209063 · BRECKENRIDGE
- 2019RIVASTIGMINEGeneric (ANDA)
ANDA 206318 · ZYDUS PHARMS
- 2019RIVASTIGMINEGeneric (ANDA)
ANDA 207308 · AMNEAL PHARMS
- 2018RIVASTIGMINEGeneric (ANDA)
ANDA 205622 · MYLAN TECHNOLOGIES
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
